Jewell M, Davis Z, Fliegelman R, Guillory J, Sokalski S
Section of Infectious Diseases, Christ Hospital and Medical Center, Oak Lawn, IL.
Chest. 1988 Apr;93(4):712-5. doi: 10.1378/chest.93.4.712.
A prospective randomized study was conducted in 200 patients undergoing coronary artery bypass surgery. All patients received intravenous (IV) cephalothin prophylaxis for 48 hours beginning with anesthetic induction. Group A (99 eligible patients) received cephalexin 500 mg po, qid for three extra days. Group B (94 eligible patients) received no oral therapy. The overall infection rate was 9.3 percent (18 patients). Six patients had multiple sites of involvement. There was no difference between group A (9.0 percent, nine patients) vs B (9.5 percent, nine patients) (p greater than 0.5). The median sternotomy infection rate, superficial or deep, was 2.6% (five patients). The surgical wound infection rate was 4.7 percent (nine patients). The overall infection rate compares favorably with that of high risk groups for clean surgical procedures defined in SENIC study. There was no advantage to prolonged oral cephalexin prophylaxis following coronary artery bypass (CAB) surgery.
对200例接受冠状动脉搭桥手术的患者进行了一项前瞻性随机研究。所有患者从麻醉诱导开始接受48小时的静脉注射头孢噻吩预防治疗。A组(99例符合条件的患者)额外3天口服头孢氨苄500毫克,每日4次。B组(94例符合条件的患者)未接受口服治疗。总体感染率为9.3%(18例患者)。6例患者有多个感染部位。A组(9.0%,9例患者)与B组(9.5%,9例患者)之间无差异(p大于0.5)。胸骨正中切开术的浅表或深部感染率中位数为2.6%(5例患者)。手术伤口感染率为4.7%(9例患者)。总体感染率与SENIC研究中定义的清洁手术高风险组的感染率相比更有利。冠状动脉搭桥(CAB)手术后延长口服头孢氨苄预防治疗并无益处。